Solid Biosciences Inc. (SLDB)
Nasdaq: SLDB · Biological Products, (No Diagnostic Substances) · Charlestown, MA · filing with the SEC since 2017
Who owns Solid Biosciences Inc.
As filed with the SECHolders of 5% or more
6
RA Capital Management, L.P. holds 11.9% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D/A filed Jun 24, 2026 says.
Directors and officers
21
report now, of 48 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Jun 24, 2026 · Common Stock, $0.001 par value per share · 9.9% in Mar 17, 2026
Perceptive Advisors LLC
SCHEDULE 13D/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 12.9% in Mar 11, 2026
Raymond Debbane
SCHEDULE 13G/A · filed May 5, 2026 · Common Stock $0.001 par value per share · 9.6% in Apr 17, 2025
BCLS II Investco, LP
SCHEDULE 13D/A · filed Mar 10, 2026 · Common Stock, $0.001 par value per share · 7.8% in Feb 21, 2025
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G · filed Jul 30, 2026 · Common Stock · 4.7% in Apr 27, 2026
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.5% in Feb 17, 2026
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock $0.001 par value per share · reported falling below 5%, from 5.14% in Nov 13, 2025
Commodore Capital LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock $0.001 par value per share · reported falling below 5%, from 7.6% in Feb 25, 2025
Camber Capital Management LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock,$0.001 par value per share · reported falling below 5%
What SLDB reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 19, 2026.
Insider tradesForm 4
29sales
0purchases
27sales on a scheduled plan
7people selling
$2.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 26, 2025 to Oct 26, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 26, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 59 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cumbo Alexander | President and CEO | 4 | $1.0M | 4 | 0 | $0 |
| Howton David T | Chief Operating Officer | 4 | $400,000 | 4 | 0 | $0 |
| Tan Kevin | CFO & Treasurer | 4 | $300,000 | 4 | 0 | $0 |
| Brooks Gabriel | Chief Medical Officer | 4 | $300,000 | 4 | 0 | $0 |
| Hanrahan Jessie | Chief Regulatory Officer | 4 | $300,000 | 4 | 0 | $0 |
| Herzich Paul | Chief Technology Officer | 4 | $300,000 | 4 | 0 | $0 |
| Ganot Ilan | CEO & President | 5 | $100,000 | 3 | 0 | $0 |